What You Should Know
- Urologic Health Inc. has closed an $11M seed financing round led by an undisclosed strategic investor, with participation from Edge Medical Ventures, SHD Partners, and Longevity Venture Partners.
- The funding supports clinical validation and the FDA 510(k) regulatory pathway for the company’s niu™ System.
- The niu™ System is designed to provide comprehensive bladder function data without catheterization, addressing conditions such as overactive bladder, urinary retention, and incontinence.
- Early feasibility studies have already demonstrated the system’s ability to capture clinically meaningful bladder activity non-invasively.
- The company will establish its headquarters in Jersey City, NJ, to prepare for its initial U.S. market entry.
Urological care currently faces a significant “diagnostic barrier.” While hundreds of millions of people worldwide suffer from bladder dysfunction, existing urodynamic tools are highly invasive and uncomfortable, leading many patients to avoid necessary clinical assessments. Urologic Health is addressing this friction with the niu™ System, a technology designed to deliver comprehensive data without the need for traditional catheterization.
Adam Yaacov, Co-founder and CEO, noted that while treatments for urological conditions have evolved, the invasive diagnostic process has remained a major challenge for both patients and clinicians.
A New Era for Urodynamics: The niu™ System
The niu™ System aims to transition bladder function assessment from an invasive procedure into a routine, repeatable, and painless clinical event.
- Routine Monitoring: Because it is non-invasive, the system supports longitudinal monitoring, allowing clinicians to track bladder health over time rather than relying on one-time invasive snapshots.
- Clinician-Friendly: The system is designed to be easier for clinical teams to perform, potentially increasing the throughput of diagnostic visits.
- AI-Driven Insights: Co-founded by Dr. Noam Omer and Adam Yaacov, the company leverages expertise in AI-driven insights to transform raw bladder activity into actionable diagnostic data.
Venture Creation and Global Operations
Urologic Health was founded and incubated at the MEDX Xelerator venture studio (now EdgeLabs). This unique venture creation model combines engineering talent in Israel with operational support in the United States to accelerate the path to market.
Shai Policker, Managing Partner of Edge Medical Ventures and chairman of Urologic’s board, emphasized that this collaborative model helps high-potential medical device companies move faster through the complex stages of clinical validation and regulatory execution.
